Costello K, Conway K
Department of Neurology, Maryland Center for Multiple Sclerosis, University of Maryland, Baltimore 21201, USA.
Rehabil Nurs. 1997 Mar-Apr;22(2):62-6, 81. doi: 10.1002/j.2048-7940.1997.tb01735.x.
In 1993, recombinant interferon beta-1b (Betaseron, Berlex Laboratories) was approved by the Food and Drug Administration as a treatment for relapsing-remitting multiple sclerosis (MS). Betaseron is the first therapeutic agent licensed for use with therapeutic patients with MS in more than 20 years. Many patients and their families have expressed great interest in obtaining information about this agent. In response, MS centers throughout the United States have developed Betaseron training programs. This article describes how rehabilitation nurses can educate patients and families about Betaseron.
